Kühne Holding, a holding company, agreed to acquire Aenova, a contract drug manufacturer, from BC Partners, a private equity firm. BC Partners will reinvest alongside Kühne Holding and continue to support Aenova as a minority shareholder. Financial terms were not disclosed. "With this investment, we are taking an important strategic step to enlarge our investment portfolio to include healthcare and pharmaceutical assets with a strong financial base and long-term growth prospects. Aenova is on a great performance track, and we are excited to accelerate it even further under our ownership," Dominik de Daniel, Kühne Holding CEO.